Pectoralis major muscle atrophy is associated with mitochondrial energy wasting in cachectic patients with gastrointestinal cancer.


Journal

Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883

Informations de publication

Date de publication:
06 2022
Historique:
revised: 19 01 2022
received: 03 08 2021
accepted: 28 02 2022
pubmed: 23 3 2022
medline: 11 6 2022
entrez: 22 3 2022
Statut: ppublish

Résumé

Cancer cachexia is a multifactorial syndrome characterized by involuntary and pathological weight loss, mainly due to skeletal muscle wasting, resulting in a decrease in patients' quality of life, response to cancer treatments, and survival. Our objective was to investigate skeletal muscle alterations in cachectic cancer patients. This is a prospective study of patients managed for pancreatic or colorectal cancer with an indication for systemic chemotherapy (METERMUCADIG - NCT02573974). One lumbar CT image was used to determine body composition. Patients were divided into three groups [8 noncachectic (NC), 18 with mild cachexia (MC), and 19 with severe cachexia (SC)] based on the severity of weight loss and muscle mass. For each patient, a pectoralis major muscle biopsy was collected at the time of implantable chamber placement. We used high-resolution oxygraphy to measure mitochondrial muscle oxygen consumption on permeabilized muscle fibres. We also performed optical and electron microscopy analyses, as well as gene and protein expression analyses. Forty-five patients were included. Patients were 67% male, aged 67 years (interquartile range, 59-77). Twenty-three (51%) and 22 (49%) patients were managed for pancreatic and colorectal cancer, respectively. Our results show a positive correlation between median myofibres area and skeletal muscle index (P = 0.0007). Cancer cachexia was associated with a decrease in MAFbx protein expression (P < 0.01), a marker of proteolysis through the ubiquitin-proteasome pathway. Mitochondrial oxygen consumption related to energy wasting was significantly increased (SC vs. NC, P = 0.028) and mitochondrial area tended to increase (SC vs. MC, P = 0.056) in SC patients. On the contrary, mitochondria content and networks remain unaltered in cachectic cancer patients. Finally, our results show no dysfunction in lipid storage and endoplasmic reticulum homeostasis. This clinical protocol brings unique data that provide new insight to mechanisms underlying muscle wasting in cancer cachexia. We report for the first time an increase in mitochondrial energy wasting in the skeletal muscle of severe cachectic cancer patients. Additional clinical studies are essential to further the exploring and understanding of these alterations.

Sections du résumé

BACKGROUND
Cancer cachexia is a multifactorial syndrome characterized by involuntary and pathological weight loss, mainly due to skeletal muscle wasting, resulting in a decrease in patients' quality of life, response to cancer treatments, and survival. Our objective was to investigate skeletal muscle alterations in cachectic cancer patients.
METHODS
This is a prospective study of patients managed for pancreatic or colorectal cancer with an indication for systemic chemotherapy (METERMUCADIG - NCT02573974). One lumbar CT image was used to determine body composition. Patients were divided into three groups [8 noncachectic (NC), 18 with mild cachexia (MC), and 19 with severe cachexia (SC)] based on the severity of weight loss and muscle mass. For each patient, a pectoralis major muscle biopsy was collected at the time of implantable chamber placement. We used high-resolution oxygraphy to measure mitochondrial muscle oxygen consumption on permeabilized muscle fibres. We also performed optical and electron microscopy analyses, as well as gene and protein expression analyses.
RESULTS
Forty-five patients were included. Patients were 67% male, aged 67 years (interquartile range, 59-77). Twenty-three (51%) and 22 (49%) patients were managed for pancreatic and colorectal cancer, respectively. Our results show a positive correlation between median myofibres area and skeletal muscle index (P = 0.0007). Cancer cachexia was associated with a decrease in MAFbx protein expression (P < 0.01), a marker of proteolysis through the ubiquitin-proteasome pathway. Mitochondrial oxygen consumption related to energy wasting was significantly increased (SC vs. NC, P = 0.028) and mitochondrial area tended to increase (SC vs. MC, P = 0.056) in SC patients. On the contrary, mitochondria content and networks remain unaltered in cachectic cancer patients. Finally, our results show no dysfunction in lipid storage and endoplasmic reticulum homeostasis.
CONCLUSIONS
This clinical protocol brings unique data that provide new insight to mechanisms underlying muscle wasting in cancer cachexia. We report for the first time an increase in mitochondrial energy wasting in the skeletal muscle of severe cachectic cancer patients. Additional clinical studies are essential to further the exploring and understanding of these alterations.

Identifiants

pubmed: 35316572
doi: 10.1002/jcsm.12984
pmc: PMC9178397
doi:

Banques de données

ClinicalTrials.gov
['NCT02573974']

Types de publication

Clinical Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1837-1849

Subventions

Organisme : Canceropole Grand Ouest
Organisme : Ligue Nationale Contre le Cancer
Organisme : Institut National du Cancer
Organisme : French Society of Clinical Nutrition and Metabolism
Organisme : French Ministry of Higher Education, Research and Innovation

Informations de copyright

© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.

Références

Front Physiol. 2019 Feb 18;10:41
pubmed: 30833900
J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1837-1849
pubmed: 35316572
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Am J Clin Nutr. 2020 Mar 1;111(3):570-579
pubmed: 31968072
Biochim Biophys Acta Rev Cancer. 2018 Dec;1870(2):137-150
pubmed: 30059724
Am J Physiol Regul Integr Comp Physiol. 2019 Jul 1;317(1):R68-R82
pubmed: 31017805
PLoS One. 2014 Jan 03;9(1):e83618
pubmed: 24404136
J Gastrointest Surg. 2008 Jul;12(7):1193-201
pubmed: 18347879
J Cachexia Sarcopenia Muscle. 2015 Mar;6(1):53-61
pubmed: 26136412
Nat Med. 2016 Jun;22(6):666-71
pubmed: 27135739
Cancers (Basel). 2019 Aug 28;11(9):
pubmed: 31466311
Front Physiol. 2021 Apr 12;12:625417
pubmed: 33912068
Semin Cell Dev Biol. 2016 Jun;54:11-9
pubmed: 26564688
J Cell Physiol. 2019 Jul;234(7):11315-11329
pubmed: 30565689
Oncotarget. 2020 Sep 22;11(38):3502-3514
pubmed: 33014286
Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006
pubmed: 18923576
Clin Cancer Res. 2015 Apr 1;21(7):1734-40
pubmed: 25370466
J Cachexia Sarcopenia Muscle. 2021 Apr;12(2):252-273
pubmed: 33783983
Int J Mol Sci. 2020 Dec 04;21(23):
pubmed: 33291708
J Cachexia Sarcopenia Muscle. 2020 Jun;11(3):735-747
pubmed: 31989803
J Clin Oncol. 2015 Jan 1;33(1):90-9
pubmed: 25422490
Curr Opin Clin Nutr Metab Care. 2015 May;18(3):221-5
pubmed: 25769061
Exp Gerontol. 2017 Jan;87(Pt A):92-99
pubmed: 27847330
Clin Exp Pharmacol Physiol. 2016 May;43(5):522-7
pubmed: 26857538
Biochim Biophys Acta Mol Basis Dis. 2020 May 1;1866(5):165674
pubmed: 31926263
J Cachexia Sarcopenia Muscle. 2019 Dec;10(6):1356-1377
pubmed: 31307124
Am J Physiol Cell Physiol. 2020 Oct 1;319(4):C700-C719
pubmed: 32783651
Nat Commun. 2015 Apr 10;6:6670
pubmed: 25858807
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
Muscle Nerve. 2008 Oct;38(4):1246-53
pubmed: 18785187
Am J Physiol Endocrinol Metab. 2014 Sep 15;307(6):E469-84
pubmed: 25096180
J Appl Physiol (1985). 2004 Dec;97(6):2333-8
pubmed: 15310748
J Cachexia Sarcopenia Muscle. 2011 Jun;2(2):111-117
pubmed: 21766057
Front Oncol. 2020 Mar 04;10:298
pubmed: 32195193
Appl Sci (Basel). 2021 Mar;11(5):
pubmed: 33898062
J Cachexia Sarcopenia Muscle. 2020 Dec;11(6):1413-1428
pubmed: 33053604
FASEB J. 2016 Sep;30(9):3053-68
pubmed: 27206451
J Muscle Res Cell Motil. 2019 Mar;40(1):59-65
pubmed: 30945134
Am J Clin Nutr. 2006 Jun;83(6):1345-50
pubmed: 16762946
J Cachexia Sarcopenia Muscle. 2012 Dec;3(4):265-75
pubmed: 22648737
Cancers (Basel). 2019 Dec 03;11(12):
pubmed: 31817027

Auteurs

Adeline Dolly (A)

Université de Tours, Inserm UMR1069, Nutrition, Croissance et Cancer, Tours, France.

Thierry Lecomte (T)

Université de Tours, Inserm UMR1069, Nutrition, Croissance et Cancer, Tours, France.
Department of hepatogastroenterology and digestive oncology, University Hospital of Tours, Tours, France.

Nicolas Tabchouri (N)

Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, University Hospital of Tours, Tours, France.

Morgane Caulet (M)

Department of hepatogastroenterology and digestive oncology, University Hospital of Tours, Tours, France.

Nicolas Michot (N)

Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, University Hospital of Tours, Tours, France.

Benjamin Anon (B)

Department of hepatogastroenterology and digestive oncology, University Hospital of Tours, Tours, France.

Romain Chautard (R)

Department of hepatogastroenterology and digestive oncology, University Hospital of Tours, Tours, France.

Yoann Desvignes (Y)

Delegation for Clinical Research and Innovation (DRCI), University Hospital of Tours, Tours, France.

Mehdi Ouaissi (M)

Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, University Hospital of Tours, Tours, France.

Gaëlle Fromont-Hankard (G)

Université de Tours, Inserm UMR1069, Nutrition, Croissance et Cancer, Tours, France.
Department of Pathology, University Hospital of Tours, Tours, France.

Jean-François Dumas (JF)

Université de Tours, Inserm UMR1069, Nutrition, Croissance et Cancer, Tours, France.

Stéphane Servais (S)

Université de Tours, Inserm UMR1069, Nutrition, Croissance et Cancer, Tours, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH